ArticleDer Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft2019
[Epidemiology of severe visual impairment and blindness of old people in Germany].
Article in Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 24 citations in OpenAlex.
- [TOVIS pilot study-Aftercare effects of teleophthalmological diagnostics in senior living].Die Ophthalmologie · 2026Article
- [Real-life data of the IVI interval after switching to faricimab therapy].Die Ophthalmologie · 2026Article
- Economic and Medical Burden of Non-Exudative Age-Related Macular Degeneration in Germany: A Retrospective Observational Claims Data Study.Clinical ophthalmology (Auckland, N.Z.) · 2025Article
- [Digital remote monitoring of chronic retinal conditions-A clinical future tool? : Remote monitoring of chronic retinal conditions].Die Ophthalmologie · 2024Review
- Epidemiology of Diagnosed Age-related Macular Degeneration in Germany: An Evaluation of the Prevalence Using AOK PLUS Claims Data.Ophthalmology and therapy · 2024Article
- Decline in Blindness in Persons Up to Age 65 and the Associated Lost Years of Gainful Employment.Deutsches Arzteblatt international · 2024Article
- [Global ophthalmology : Update].Die Ophthalmologie · 2024Article
- Cross-sectional study investigating the prevalence and causes of vision impairment in Northwest Portugal using capture-recapture.BMJ open · 2022Article
- [Scientific performance of ophthalmological research institutions in Germany 2018-2020 : Studies, publications, third-party funding and more-The research map of the German Ophthalmological Society (DOG)].Die Ophthalmologie · 2022Article
- Progression to severe visual impairment and blindness in POAG patients: pace and risk factors-a cohort study using German health claims data.BMJ open ophthalmology · 2022Article
- Anti-VEGF therapies for age-related macular degeneration: a powerful tactical gear or a blunt weapon? The choice is ours.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021Review
- Markedly decreasing incidence of cause-specific blindness in Saxony (Eastern Germany).Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2021Review
- The Diagnosis and Treatment of Age-Related Macular Degeneration.Deutsches Arzteblatt international · 2020Review
- Economic burden of blindness and visual impairment in Germany from a societal perspective: a cost-of-illness study.The European journal of health economics : HEPAC : health economics in prevention and care · 2020Article
- [Ophthalmology 2019-where do we stand? : An analysis of the treatment situation in Germany].Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately 500,000 blind and 1 million visually impaired persons live in Germany, which lacks a national blind registry. Therefore data from social welfare agencies and population-based studies are used to estimate prevalence and incidence. Main causes for severe visual impairment and blindness are age-related macular degeneration, glaucoma and diabetic eye diseases. We observed a relative decline of the incidence of severe visual impairment and blindness over the last decades, which is primarily due to improved ophthalmic care and better treatment options. However, the absolute number of subjects with severe visual impairment and blindness increases due to population ageing. This will cause significant social and economic challenges in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.